In vitro, Linifanib was a potent FLT3 inhibitor with an IC50 value of 100 nM in normal human blood-spiked AML patients [100] and potentiated FLT3 kinase inhibition compared with other agents like Sorafenib [96]. The gene discussed is FLT3; the disease is acute myeloid leukemia.